- Conditions
- Thoracic Aortic Aneurysm
- Interventions
- TEVAR, Non-TEVAR medical treatment
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Multigated Acquisition Scan, Positron Emission Tomography, Transplant Conditioning, X-Ray Imaging
- Procedure · Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Aortic Stenosis
- Interventions
- Transthoracic echocardiogram
- Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • New York, New York • Houston, Texas
- Conditions
- Heart Failure and Reduced Ejection Fraction, Functional Mitral Regurgitation
- Interventions
- Cardiac MRI
- Diagnostic Test
- Lead sponsor
- Minneapolis Heart Institute Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Minneapolis, Minnesota • Charlotte, North Carolina • Cincinnati, Ohio + 2 more
- Conditions
- Cardiac Resynchronization Therapy, Chronic Heart Failure, Left Bundle-Branch Block
- Interventions
- CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment
- Device
- Lead sponsor
- XSpline S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Durham, North Carolina
- Conditions
- Amyloidosis, Primary, Cardiomyopathy
- Interventions
- F-18 florbetapir/C-11 acetate PET, MRI, N-13 ammonia PET
- Radiation · Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer With Low to Intermediate HER2 Expression
- Interventions
- Echocardiogram
- Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 79 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube High Grade Serous Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian Low Grade Serous Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma
- Interventions
- Biospecimen Collection, Cediranib Maleate, Computed Tomography, Computed Tomography with Contrast, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 384
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more
- Conditions
- Coronary Atherosclerosis, Myocardial Infarction, Coronary Plaque Embolization
- Interventions
- Embolic Protection Device (EPD), Intracoronary Spectroscopy and Ultrasonic Evaluation, Angioplasty and Stent Implant
- Device
- Lead sponsor
- Infraredx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • San Francisco, California • Washington D.C., District of Columbia + 6 more
- Conditions
- Breast Neoplasms, Lymphoma, Sarcoma
- Interventions
- Echocardiogram
- Procedure
- Lead sponsor
- Daniel Rushing
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Arrhythmias, Cardiac, Bradycardia, Tachycardia
- Interventions
- cardiac implantable electronic devices (CIEDs)
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Gainesville, Florida • Macon, Georgia • Portland, Oregon + 5 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Hematopoietic Cell Transplantation, Idarubicin Hydrochloride, Multigated Acquisition Scan, Pembrolizumab, Punch Biopsy
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Orange, California • New Haven, Connecticut + 7 more
- Conditions
- Coronary Artery Disease
- Interventions
- CT-guided PCI, IVUS-guided PCI
- Device
- Lead sponsor
- CoreAalst BV
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,090 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Minneapolis, Minnesota • Roslyn, New York
- Conditions
- Atrial Flutter
- Interventions
- 3D electroanatomical mapping alone guided CTI ablation, ICE plus 3D electroanatomical mapping guided CTI ablation
- Procedure
- Lead sponsor
- Kansas City Heart Rhythm Research Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Overland Park, Kansas
- Conditions
- Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Neuroblastoma, Refractory Childhood Osteosarcoma, Refractory Neuroblastoma, Refractory Osteosarcoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine Phosphate, GD2-CAR-expressing Autologous T-lymphocytes, Imaging Procedure, Magnetic Resonance Imaging of the Heart, Multigated Acquisition Scan, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 40 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2040
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 3 more
- Conditions
- Peripheral Arterial Disease
- Interventions
- Percutaneous Peripheral Intervention, Optical Coherence Tomography, Ankle Brachial Index, Six minute walk distance, Aspirin, Aspirin + Ticagrelor
- Procedure · Device · Other + 1 more
- Lead sponsor
- Arkansas Heart Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
- Interventions
- Rituximab, Etoposide, Copanlisib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, ECHO, EKG, MRI Brain, 18F-FDG - PET, CT Scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP)
- Biological · Drug · Diagnostic Test + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Microvascular Coronary Dysfunction, Cardiovascular Disease
- Interventions
- Coronary Angiography, Coronary Reactivity Testing, Cardiac Magnetic Resonance Imaging, Cardiac Magnetic Resonance Angiography, Computed Coronary Tomographic Angiography, Rest-Stress Millar Testing, Aortic vasorelaxation tests
- Procedure
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2030
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Ischemic Stroke
- Interventions
- Active Sphenopalatine Ganglion (SPG) Stimulation, Sham Sphenopalatine Ganglion (SPG) Stimulation
- Device
- Lead sponsor
- BrainsGate
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 7
- States / cities
- Sarasota, Florida • Winfield, Illinois • Greensboro, North Carolina + 3 more
- Conditions
- Heart Failure, Systolic
- Interventions
- CMR/CTA Guidance for CRT
- Diagnostic Test
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 20 Years to 90 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Cardiology, Radiology, Stenoses
- Interventions
- CT-FFR and CTP
- Device
- Lead sponsor
- Lancaster General Hospital
- Other
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- PET, Laboratory Testing, Safety Testing, F18-FFNP
- Radiation · Other · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Indication for PICC Placement
- Interventions
- Chest X-ray, Sherlock 3CG® TCS, Peripherally Inserted Central Catheter (PICC)
- Device · Procedure
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Maitland, Florida • Baltimore, Maryland • Salisbury, Maryland + 1 more
- Conditions
- Sudden Cardiac Death
- Interventions
- Electrophysiology study (EPS), Standard Care, Cardiac Magnetic Resonance (CMR)
- Procedure · Other
- Lead sponsor
- Western Sydney Local Health District
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,058 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts